Shots:
- United Therapeutics has acquired Thymmune Therapeutics, incl. its lead asset THY-100, developed for the treatment of congenital athymia
- Under the deal, United Therapeutics has acquired Thymmune for $140M upfront, with up to $160M in additional earn-out payments tied to clinical & regulatory milestones through 2031
- THY-100 is a preclinical regenerative therapy for congenital athymia that showed formation of an in vivo neo-thymus to restore T-cell development, with potential applications in transplant tolerance, immune-mediated diseases, & age-related immune decline
Ref: Businesswire | Image: Thymmune | Press Release
Related News: Ipsen to Acquire Kartos Therapeutics for ~$1.75B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
